Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David O. Watson Sells 4,965 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David O. Watson sold 4,965 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $28.70, for a total value of $142,495.50. Following the completion of the sale, the general counsel now directly owns 107,756 shares in the company, valued at $3,092,597.20. This represents a 4.40 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Apellis Pharmaceuticals Price Performance

Shares of Apellis Pharmaceuticals stock traded down $0.90 during trading on Tuesday, hitting $27.69. 1,695,048 shares of the company’s stock traded hands, compared to its average volume of 2,610,431. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The firm’s fifty day moving average price is $31.87 and its 200 day moving average price is $33.55. Apellis Pharmaceuticals, Inc. has a twelve month low of $24.34 and a twelve month high of $71.90. The company has a market cap of $3.44 billion, a PE ratio of -13.64 and a beta of 0.94.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm had revenue of $196.83 million for the quarter, compared to the consensus estimate of $200.00 million. During the same period in the prior year, the business earned ($1.17) earnings per share. The company’s revenue for the quarter was up 78.3% on a year-over-year basis. Analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.72 earnings per share for the current year.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Institutional investors have recently modified their holdings of the business. HighVista Strategies LLC grew its holdings in Apellis Pharmaceuticals by 4.1% during the second quarter. HighVista Strategies LLC now owns 7,566 shares of the company’s stock valued at $290,000 after purchasing an additional 300 shares during the period. Amalgamated Bank lifted its position in shares of Apellis Pharmaceuticals by 5.4% in the second quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock worth $268,000 after purchasing an additional 359 shares in the last quarter. KBC Group NV lifted its position in shares of Apellis Pharmaceuticals by 34.8% in the third quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after purchasing an additional 679 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Apellis Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock worth $130,000 after acquiring an additional 781 shares in the last quarter. Finally, Wolverine Asset Management LLC bought a new stake in Apellis Pharmaceuticals during the third quarter worth $27,000. Institutional investors and hedge funds own 96.29% of the company’s stock.

Analyst Upgrades and Downgrades

APLS has been the topic of several research analyst reports. Citigroup decreased their price target on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Bank of America cut their price target on Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Mizuho lowered their price objective on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a research note on Thursday, October 24th. Piper Sandler lowered their price objective on shares of Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating for the company in a research note on Wednesday, November 6th. Finally, Oppenheimer decreased their price target on shares of Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Eight research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $46.65.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).